Abstract
Perturbations in immune processes play an important role in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), a multifactorial disorder mainly characterized by severe and prolonged fatigue and tipically affecting a variety of bodily systems including the immune system. Recent reports have shown that CFS/ME is an inflammatory disorder may be associated with autoimmune responses, mainly characterized by reduced functional activity of most immune cells, including neutrophils, natural killer cells, monocytes/macrophage and dendritic cells, together with dysregulations in cytokine levels, responsible for changes in the adaptive immune system. Interactions between gut microorganisms and host immune function have been shown to contribute to aberrant inflammation in CFS/ME patients. Commensal and/or pathogen-associated molecular patterns detected by Toll-like receptors (TLRs) expressed on intestinal epithelial cells appear to trigger inflammatory signaling cascade leading to neuroinflammation and neurodegeneration. This paper examines the role of TLR-mediated innate immunity in CFS/ME with evaluation of the current literature, also discussing about innovative therapeutic approaches represented by immunomodulators TLR-targeting.
Keywords: Chronic fatigue syndrome/myalgic encephalomyelitis, inflammation, immune response dysregulation, toll-like receptors, toll-like receptor-targeting compounds.
CNS & Neurological Disorders - Drug Targets
Title:The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
Volume: 14 Issue: 7
Author(s): Maria Elsa Gambuzza, Francesca Maria Salmeri, Luca Soraci, Giulia Soraci, Vincenza Sofo, Silvia Marino and Placido Bramanti
Affiliation:
Keywords: Chronic fatigue syndrome/myalgic encephalomyelitis, inflammation, immune response dysregulation, toll-like receptors, toll-like receptor-targeting compounds.
Abstract: Perturbations in immune processes play an important role in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), a multifactorial disorder mainly characterized by severe and prolonged fatigue and tipically affecting a variety of bodily systems including the immune system. Recent reports have shown that CFS/ME is an inflammatory disorder may be associated with autoimmune responses, mainly characterized by reduced functional activity of most immune cells, including neutrophils, natural killer cells, monocytes/macrophage and dendritic cells, together with dysregulations in cytokine levels, responsible for changes in the adaptive immune system. Interactions between gut microorganisms and host immune function have been shown to contribute to aberrant inflammation in CFS/ME patients. Commensal and/or pathogen-associated molecular patterns detected by Toll-like receptors (TLRs) expressed on intestinal epithelial cells appear to trigger inflammatory signaling cascade leading to neuroinflammation and neurodegeneration. This paper examines the role of TLR-mediated innate immunity in CFS/ME with evaluation of the current literature, also discussing about innovative therapeutic approaches represented by immunomodulators TLR-targeting.
Export Options
About this article
Cite this article as:
Gambuzza Elsa Maria, Salmeri Maria Francesca, Soraci Luca, Soraci Giulia, Sofo Vincenza, Marino Silvia and Bramanti Placido, The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?, CNS & Neurological Disorders - Drug Targets 2015; 14 (7) . https://dx.doi.org/10.2174/1871527314666150325235247
DOI https://dx.doi.org/10.2174/1871527314666150325235247 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Viral Infection - A Cure for Type 1 Diabetes?
Current Medicinal Chemistry Immunotherapy for Conformational Diseases
Current Pharmaceutical Design Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Microbiota Regulation of Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Immunomodulation of the Allergic Inflammatory Response: New Developments
Inflammation & Allergy - Drug Targets (Discontinued) Multiple Roles of Histamine in Autoimmune Demyelinating Disease of the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases
Current Pharmaceutical Design Respiratory Tolerance in the Protection Against Asthma
Current Drug Targets - Inflammation & Allergy Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis
Medicinal Chemistry GPR30 Forms an Integral Part of E2-Protective Pathway in Experimental Autoimmune Encephalomyelitis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology